Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60. https://doi.org/10.1016/S0140-6736(20)31286-1.

Article  CAS  PubMed  Google Scholar 

Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018;3(4): e98006. https://doi.org/10.1172/jci.insight.98006.

Article  PubMed  PubMed Central  Google Scholar 

Moniaga CS, Tominaga M, Takamori K. The pathology of Type 2 inflammation-associated itch in atopic dermatitis. Diagnostics (Basel). 2021;11(11):2090. https://doi.org/10.3390/diagnostics11112090.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6. https://doi.org/10.1038/ng1767.

Article  CAS  PubMed  Google Scholar 

Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13(1):15–26. https://doi.org/10.1080/1744666X.2016.1212660.

Article  CAS  PubMed  Google Scholar 

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. https://doi.org/10.1111/all.13954.

Article  CAS  PubMed  Google Scholar 

Bieber T. Targeting T2 inflammation by dupilumab impacts on the microbiomic “Menage a Trois” of atopic dermatitis. J Invest Dermatol. 2020;140(1):15–7. https://doi.org/10.1016/j.jid.2019.07.680.

Article  CAS  PubMed  Google Scholar 

About Biomarkers and Qualification. U.S. Food & Drug Administration. 2021. Available from: https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification#what-is. Accessed 31 May 2024.

Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis Is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480–9. https://doi.org/10.1016/j.jid.2018.12.018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, et al. Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1. Am J Clin Dermatol. 2024;25(1):139–48. https://doi.org/10.1007/s40257-023-00817-0.

Article  PubMed  Google Scholar 

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. https://doi.org/10.1111/bjd.19574.

Article  CAS  PubMed  Google Scholar 

Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596–605. https://doi.org/10.1001/jamadermatol.2023.0627.

Article  PubMed  PubMed Central  Google Scholar 

Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–24. https://doi.org/10.1016/j.jaad.2022.07.019.

Article  CAS  PubMed  Google Scholar 

Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The eczema area and severity index-a practical guide. Dermatitis. 2022;33(3):187–92. https://doi.org/10.1097/DER.0000000000000895.

Article  PubMed  PubMed Central  Google Scholar 

Simpson EL, Tom WL, Bushmakin AG, Cappelleri JC, Yosipovitch G, Stander S, et al. Relationship among treatment, pruritus, investigator’s static global assessment, and quality of life in patients with atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(2):587–98. https://doi.org/10.1007/s13555-021-00506-y.

Article  PubMed  PubMed Central  Google Scholar 

Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–21. https://doi.org/10.1111/bjd.15641.

Article  CAS  PubMed  Google Scholar 

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9. https://doi.org/10.1111/bjd.17744.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Biomarkers in atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1163–8. https://doi.org/10.1016/j.jaci.2023.01.019.

Article  PubMed  Google Scholar 

Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174–90. https://doi.org/10.1016/j.jaci.2021.01.013. (e1).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Libon F, Caron J, Nikkels AF. Biomarkers in atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(7):1729–38. https://doi.org/10.1007/s13555-024-01193-1.

Article  PubMed  PubMed Central  Google Scholar 

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools). Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/ Co-published by National Institutes of Health (US), Bethesda (MD); 2016.

Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. https://doi.org/10.1016/j.jaci.2018.10.032.

Article  PubMed  Google Scholar 

Biomarkers. In: Understand Translational Research Tools. U.S. Department of Health and Human Services. 2024. Available from: https://toolkit.ncats.nih.gov/module/discovery/developing-translational-research-tools/biomarkers/. Accessed 10 Apr 2024.

Noda S, Suarez-Farinas M, Ungar B, Kim SJ, de Guzman SC, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–64. https://doi.org/10.1016/j.jaci.2015.08.015.

Article  CAS  PubMed  Google Scholar 

Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–63. https://doi.org/10.1016/j.jaci.2021.01.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, et al. Atopic dermatitis in African American patients is T(H)2/T(H)22-skewed with T(H)1/T(H)17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99–110. https://doi.org/10.1016/j.anai.2018.08.024. (e6).

Article  CAS  PubMed  Google Scholar 

Yu L, Li L. Potential biomarkers of atopic dermatitis. Front Med (Lausanne). 2022;9:1028694. https://doi.org/10.3389/fmed.2022.1028694.

Article  PubMed  PubMed Central  Google Scholar 

Ott H, Stanzel S, Ocklenburg C, Merk HF, Baron JM, Lehmann S. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children. Acta Derm Venereol. 2009;89(3):257–61. https://doi.org/10.2340/00015555-0627.

Article  PubMed  Google Scholar 

Simpson EL, De Benedetto A, Boguniewicz M, Ong PY, Lussier S, Villarreal M, et al. Phenotypic and endotypic determinants of atopic dermatitis severity from the atopic dermatitis research network (ADRN) registry. J Allergy Clin Immunol Pract. 2023;11(8):2504–15. https://doi.org/10.1016/j.jaip.2023.04.052.

Article  CAS  PubMed